Another vaccine aces testing
US biotech firm Moderna has announced that its experimental vaccine against Covid-19 is 94.5% effective, reported AFP (16 Nov 2020). Moderna released early results from a clinical trial with more than 30 000 participants, after US pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90% effective. Both vaccine frontrunners are based on a new platform called messenger RNA, which is faster to produce than traditional vaccines and effectively turn human cells into vaccine factories.
The company plans to submit applications for emergency approval in the US and around the world within weeks and said it expects to have approximately 20-million doses ready to ship in the US by the end of the year.
“It is not yet clear how long lasting the protection will be from either the Moderna or Pfizer vaccines, nor how well they work for the elderly, the age-group at highest risk from Covid-19.”